Cilostazol Stroke Prevention Study for Antiplatelet Combination
Status:
Completed
Trial end date:
2018-12-07
Target enrollment:
Participant gender:
Summary
To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol
(Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for
secondary prevention of ischemic stroke in high-risk patients for stroke